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Abstract
Background: Multimorbidity is prevalent for people with myocardial infarction (MI), yet previous studies
investigated single-health conditions in isolation. We identified patterns of multimorbidity in MI survivors and their
associations with changes in HRQoL.
Methods: In this national longitudinal cohort study, we analysed data from 9566 admissions with MI from 77
National Health Service hospitals in England between 2011 and 2015. HRQoL was measured using EuroQol 5
dimension (EQ5D) instrument and visual analogue scale (EQVAS) at hospitalisation, 6, and 12 months following MI.
Latent class analysis (LCA) of pre-existing long-term health conditions at baseline was used to identify clusters of
multimorbidity and associations with changes in HRQoL quantified using mixed effects regression analysis.
Results: Of 9566 admissions with MI (mean age of 64.1 years [SD 11.9], 7154 [75%] men), over half (5119 [53.5%]
had multimorbidities. LCA identified 3 multimorbidity clusters which were severe multimorbidity (591; 6.5%) with
low HRQoL at baseline (EQVAS 59.39 and EQ5D 0.62) which did not improve significantly at 6 months (EQVAS 59.92,
EQ5D 0.60); moderate multimorbidity (4301; 47.6%) with medium HRQoL at baseline (EQVAS 63.08, EQ5D 0.71) and
who improved at 6 months (EQVAS 71.38, EQ5D 0.76); and mild multimorbidity (4147, 45.9%) at baseline (EQVAS
64.57, EQ5D 0.75) and improved at 6 months (EQVAS 76.39, EQ5D 0.82). Patients in the severe and moderate groups
were more likely to be older, women, and presented with NSTEMI. Compared with the mild group, increased
multimorbidity was associated with lower EQ-VAS scores (adjusted coefficient: −5.12 [95% CI −7.04 to −3.19] and
−0.98 [−1.93 to −0.04] for severe and moderate multimorbidity, respectively.
The severe class was more likely than the mild class to report problems in mobility, OR 9.62 (95% confidence
interval: 6.44 to 14.36), self-care 7.87 (4.78 to 12.97), activities 2.41 (1.79 to 3.26), pain 2.04 (1.50 to 2.77), and anxiety/
depression 1.97 (1.42 to 2.74).
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Conclusions: Among MI survivors, multimorbidity clustered into three distinct patterns and was inversely
associated with HRQoL. The identified multimorbidity patterns and HRQoL domains that are mostly affected may
help to identify patients at risk of poor HRQoL for which clinical interventions could be beneficial to improve the
HRQoL of MI survivors.
Trial registration: ClinicalTrials.gov NCT01808027 and NCT01819103
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Background
Multimorbidity, the presence of two or more long-term
health conditions in an individual, is a major clinical and
public health challenge [1, 2]. Around two thirds of
patients with cardiovascular diseases have at least one
long-term health condition [3]. Co-morbidities are
present in 60% of patients hospitalised with myocardial
infarction (MI) and are associated with significant years
of life lost [4]. Following MI, patients frequently report
poor health related quality of life (HRQoL), which may
not recover [5], and is independently associated with
higher rates of death at 1 year [6, 7]. Poor HRQoL is
more commonly reported among women [8, 9], older
people with frailty [5, 10], non-white ethnicity [11], and
in those that experience bleeding complications relating
to dual anti-platelet therapy [12]. Several previous stud-
ies have looked at individual chronic health conditions
and their impact on health-related quality of life in MI
survivors. Patients with long-term health conditions
such as hypertension [13], diabetes [14], angina [15], de-
pression [16], and chronic obstructive pulmonary disease
(COPD) report poor HRQoL. Specific disease combina-
tions may have greater effects than others on functional,
physical and mental status [17], quality of life [18], and
mortality [4, 19].
However, there is a paucity of longitudinal studies that
have investigated the association of multimorbidity and
temporal changes in HRQoL [20–22]. Existing studies
are limited by a focus on mortality as the primary end
point [4, 21], use of cross-sectional designs [20, 23], and
focusing on individual disease in isolation. Different dis-
ease combinations may have greater effects than others
on patient outcomes. A previous study [4] found an as-
sociation of combinations of disease clusters with patient
survival in MI patients. We have extended this research
by looking at how combinations of disease clusters in
survivors of MI impact on changes in HRQoL. Notably,
there are few large-scale datasets available that combine
clinical data with robust evaluation of temporal changes
in HRQoL for patients with MI. In this study, we identi-
fied baseline multimorbidity patterns, compare changes
in HRQoL across multimorbidity clusters, and investi-





We analysed data from Evaluation of the Methods and
Management of Acute Coronary Events, EMMACE-3
and EMMACE-4, which are multicentre longitudinal
national cohort studies of outcomes following MI com-
bining survey data with national clinical registration data
(ClinicalTrials.gov NCT01808027 and NCT01819103)
[24]. The study included patients aged 18 years and over
who were hospitalized with MI, defined by the third
universal definition as either ST-elevation myocardial in-
farction (STEMI) or non-STEMI (NSTEMI) [25]. Partici-
pants were recruited from 77 National Health Service
(NHS) hospitals in England between November 1, 2011,
and June 24, 2015. They were consented to participate
by a trained researcher during their hospital admission
(data flow is shown in Additional file 1: Figure S1).
Patients at a terminal stage of any illness, and those
for whom follow-up would be inappropriate or impracti-
cal, were excluded. Consenting patients were asked to
complete a self-administered questionnaire at the time
of enrolment in hospital, and at 1, 6, and 12 months fol-
lowing discharge from hospital. This included informa-
tion about HRQoL assessed using the three level
EuroQol 5-dimension (EQ-5D-3L) instrument [24]. For
non-responders who were alive and who had not with-
drawn from the study, repeat questionnaires were sent
by post on up to three occasions before the date of the
next follow-up contact. Data for consenting patients
were linked to the national clinical register of MI admis-
sions in the UK (Myocardial Ischaemia National Audit
Project, MINAP [26]) to gather information about pa-
tients medical history including presence of hyperten-
sion, diabetes mellitus, angina, asthma or chronic
obstructive pulmonary disease (COPD), cerebrovascular
disease (CVSD), peripheral vascular disease (PVD),
chronic heart failure, chronic renal failure, type of MI
(NSTEMI or STEMI), and in-hospital as well as post-
discharge treatments and medications.
Health-related quality of life
The outcome of this study was HRQoL assessed using
self-reported EQ-5D-3L [27]. This contains two
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subscales: a descriptive system (EQ-5D) and a visual
analogue scale (EQ-VAS). EQ-5D comprises five dimen-
sions: mobility, self-care, usual activities, pain/discom-
fort, and anxiety/depression. Each domain has three
levels (3L): no problems, some problems, and extreme
problems. The EQ-5D-3L dimensions data may be sum-
marised as a single index score ranging from −0.5 to 1,
with scores less than 0 indicating states ‘worse than
death’, 0 indicating no quality of life, or ‘death’, and 1 in-
dicating full health and therefore no problems in any do-
main. The index score was standardised to the UK
population [28]. The EQ-VAS score ranges from 0 to
100, with 0 denoting the worst and 100 the best, health
state imaginable. The EQ-5D questionnaire has previ-
ously been validated in patients following MI [29]. A dif-
ference in score of 7 for VAS and 0.05 for EQ-5D score
are regarded as clinically important [30], and these
thresholds were used to define a clinically important
change between subgroups.
Exposure
The exposure was multimorbidity clusters based on 7
pre-existing long-term health conditions recorded in the
MINAP registry including hypertension, diabetes melli-
tus, asthma or chronic obstructive pulmonary disease
(COPD), cerebrovascular disease (CVSD), peripheral vas-
cular disease (PVD), chronic heart failure, and chronic
renal failure. In the data source used for the study, the
Myocardial Ischaemia National Audit Project (MINAP)
[26] registry information on multi-morbidities is given
as binary variables. No further detail is given beyond
this; therefore, we were restricted to use the information
as recorded.
Other variables
Sociodemographic, health characteristics, and clinical vari-
ables included age, sex, ethnicity (white vs other), smoking
status (never vs ex or current), body mass index (BMI)
(kg/m2), past medical history of MI, angina, diagnosis
(STEMI or NSTEMI), revascularisation (percutaneous
coronary intervention [PCI] vs. no PCI; coronary artery
bypass graft [CABG] surgery vs no CABG surgery), medi-
cations (aspirin, β blockers, statins, and ACE inhibitors),
and referral for cardiac rehabilitation (yes/no).
Statistical analysis
Patient characteristics according to multimorbidity clus-
ters were described using frequencies and percentages
for categorical data and for continuous data as means
and standard deviation. Chi-square test and ANOVA
were used to assess univariate associations between cat-
egorical and continuous patients’ characteristics and
multimorbidity clusters, respectively. We corrected for
multiple testing in the tables using the Hochberg correc-
tion, using a false discovery rate of 0.05.
Latent class analysis (LCA) [31] using Mplus software
version 8 was used to identify clusters of multimorbidity
for 7 pre-existing long-term health conditions recorded
in the MINAP registry at hospital admission including
hypertension, diabetes mellitus, asthma or chronic ob-
structive pulmonary disease (COPD), cerebrovascular
disease (CVSD), peripheral vascular disease (PVD),
chronic heart failure, and chronic renal failure.
Latent class analysis (LCA) is a statistical technique
used to determine subgroups within populations that
share certain outward characteristics [31]. In LCA, class
membership is based on probability of belonging to a
class membership given the pattern of responses they
have on indicator variables, and there are no clear cut
assignments. LCA is a “person-centred” approach of de-
riving typologies, unlike “variable-centred” tradition that
uses arbitrary cut-offs for classifying individual cases
[32]. We used LCA instead of cluster analysis [33] be-
cause unlike cluster analysis or k-means clustering, LCA
is model-based and an evaluation of how well a pro-
posed LCA model represents the data can be conducted
[33] using Bayesian information criterion (BIC) [34],
Akaike’s information criteria (AIC) [35], and Bootstrap
likelihood ratio test (BLRT) [36] p values. We fitted sev-
eral latent class models varying the number of classes up
to 5 classes to identify the best class solution with 1000
random starting values each with 100 iterations.
Bootstrap p values based on 500 replications were used
to assess model fit. The model goodness of fit statistics,
entropy, classification matrix, class frequencies, and
class conditional probabilities is reported in
Additional file 1: Table S1, Table S2, and Table S3.
The utility of using LCA has been demonstrated by
other researchers who used it to identify clinical
phenotypes with differential treatment responses [37]
and patient outcomes [4, 38, 39].
The optimal LCA model was selected based on Bayes-
ian information criterion (BIC), Akaike’s information cri-
teria (AIC), Bootstrap likelihood ratio test (BLRT) p
values, and clinical interpretation. For the BIC and AIC
the optimal model is the model with the smallest value,
and for the BLRT, the optimal number of clusters is
where the p value becomes non-significant at signifi-
cance level 0.05. A three-class multimorbidity solution
provided the best latent class model fit based on BIC,
AIC, and BLRT p values. Patient allocation was based on
posterior probabilities of belonging to a class. In order
to determine the adjusted association of baseline patient
characteristics with multimorbidity cluster membership,
we fitted multinomial logistic regression models and re-
ported using odds ratios and their corresponding 95%
confidence intervals.
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Multilevel linear regression analysis [40] of longitu-
dinal changes in EQ-VAS scores (in hospital, 1 month, 6
months, and 12 months) was performed to investigate
the associations of multimorbidity clusters and temporal
changes in patient perceptions of health. The outcomes
data are repeated measurements overtime, and patients
are clustered within hospitals; therefore, data are not in-
dependent, and a multilevel linear model was used to ac-
count for the clustering in the data. The multilevel
models were fitted in steps, first an unconditional means
model was used to determine the significance of the 2
random-effect terms (hospital and patient). To check
whether the linear model was appropriate, we examined
the distribution of residuals to check that there were ap-
proximately normally distributed. The normal probabil-
ity plots are reported in Additional file 1: Figure S2.
Where the normality assumption was violated, the
multilevel Tobit regression [41] models were fitted and
compared to the multilevel linear model results and the
results were similar. Tobit regression models are com-
monly used to analyse patient reported outcome mea-
sures data with ceiling and floor effects.
The analysis adjusted for time (categorised as baseline,
1 month, 6 months, and 12 months), age, sex, ethnicity
(white vs other), smoking status (never vs ex or current),
past medical history of MI, angina, diagnosis (STEMI or
NSTEMI), revascularisation (percutaneous coronary
intervention [PCI] vs. no PCI; coronary artery bypass
graft [CABG] surgery vs no CABG surgery), medications
(aspirin, β blockers, statins, and ACE inhibitors), referral
for cardiac rehabilitation (yes/no), and interactions of
time and multimorbidity class. The confounders were
selected based on clinical consideration and previous re-
search [4, 42].
Multilevel linear regression analysis of longitudinal
changes in EQ-5D scores (in hospital, 1 month, 6
months, and 12 months) was performed to investigate
the associations of multimorbidity clusters and temporal
changes in HRQoL. Effect sizes (regression coefficients)
and their corresponding 95% confidence intervals were
used to assess the adjusted magnitude of the difference
in EQ-VAS, EQ-5D scores across multimorbidity classes.
To investigate the association of multimorbidity clus-
ters and changes in HRQoL measured by EQ-5D dimen-
sions, five multilevel logistic regression models were
fitted for the EQ-5D dimensions (mobility, self-care, ac-
tivities, pain, and anxiety, and depression) adjusting for
age, sex, ethnicity (white versus other) smoking status
(never vs ex or current), past medical history of MI, an-
gina, diagnosis (STEMI or NSTEMI), revascularisation
(percutaneous coronary intervention [PCI] vs. no PCI;
coronary artery bypass graft [CABG] surgery vs no
CABG surgery), medications (beta-blockers, statins,
angiotensin converting enzymes (ACE), aspirin), cardiac
rehabilitation (yes/no), and interactions of time and
multimorbidity.
The ‘extreme problem’ category for some domains of
the EQ5D measure was endorsed by few individuals for
some domains (e.g., self-care and mobility); therefore,
we combined the EQ-5D levels ‘some problems’ and ‘ex-
treme problems’ and the responses were binary (no
problems vs some/extreme problems) and adjusted odds
ratios (OR) and their corresponding 95% confidence in-
tervals were used to assess the adjusted associations of
multimorbidity classes and EQ-5D dimensions.
Missing data
In longitudinal studies, missing data are commonly en-
countered, subjects can be missed at a particular assess-
ment time; therefore, subjects may provide outcome
data at some, but not all study time points resulting in
incomplete data. Participants might drop out of the
study or could be lost to follow up. In this study, there
was missing outcome data over time. A sensitivity ana-
lysis was conducted comparing baseline characteristics
of patients with complete data and those that dropped
out (Additional file 1: Table S4). The drop outs were not
significantly different from the followed up subjects in
sex, ethnicity, previous angina, chronic renal failure, and
PVD but were significantly different in age, diagnosis
(NSTEMI, STEMI), Index of Multiple Deprivation
(IMD), smoking status, history of previous acute MI
(AMI), PCI, prevalence of diabetes, baseline EQ-5D, and
EQ-VAS scores. In order to include patients with incom-
plete outcome data and to mitigate against biases which
may arise as a result of such an omission, we used a
multilevel model that includes all participants even if
they were not assessed at all 4 time points.
All statistical tests were two-sided, and statistical sig-
nificance was considered at p <0.05. Analyses were con-
ducted using stata (IC) version 15
Patient involvement
Whilst no patients were involved in setting the research
question or the study design, we have co-produced this
research manuscript with a patient with prior MI who
provided input into the interpretation of the research
findings, gave a critical review of the manuscript, and




Descriptive statistics for the cohort are shown in Table 1.
From 16,780 acute coronary syndrome hospitalisations
across the 77 recruiting hospitals in England between
2010 and 2015, we excluded 4250 who did not have a
diagnosis of MI and 2964 non-index hospitalisations,
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Multimorbidity class 3 (mild)
4147 (45.9%)
P value†
Age, mean (SD) 64.1
(11.9)
74.8 (9.3) 68.8 (10.3) 57.7 (10.5) <0.001*
Women, n (%) 2384
(24.9)
177 (30.0) 1274 (29.7) 803 (19.4) <0.001*
IMD, mean (SD) 23.0
(15.7)
24.0 (16.2) 22.3 (15.2) 23.7 (16.1) 0.04










368 (64.6) 2709 (64.2) 5979 (67.2) <0.001*
NSTEMI, n (%) 5658
(59.2)
508 (86.0) 2870 (66.7) 2046 (49.3) <0.001*
STEMI, n (%) 3908
(40.8)
83 (14.0) 1431 (33.3) 2101 (50.7)
Co-morbidities
Diabetes, n (%) 1714
(17.9)
375 (64.7) 1143 (27.1) 107 (2.6) <0.001*
Peripheral vascular
disease, n (%)
317 (3.3) 121 (20.5) 168 (3.9) 24 (0.6) <0.001*
Cerebrovascular
disease, n (%)
428 (4.5) 122 (20.6) 297 (6.9) 0 <0.001*




147 (24.9) 651 (15.1) 358 (8.6) <0.001*
Chronic renal failure, n
(%)
289 (3.0) 235 (39.8) 45 (1.1) 8 (0.2) <0.001*
Heart failure, n (%) 212 (2.2) 203 (34.4) 0 6 (0.1) <0.001*
Hypertension, n (%) 4078
(42.6)
408 (69.0) 3295 (76.6) 337 (8.1) <0.001*
Previous MI, n (%) 1522
(15.9)
384 (65.0) 1006 (23.4) 114 (2.8) <0.001*
Angina, n (%) 1792
(18.7)
374 (63.3) 1322 (30.7) 80 (1.9) <0.001*
Previous PCI, n (%) 899 (9.4) 169 (28.7) 617 (14.4) 98 (2.4) <0.001*
CABG surgery, n (%) 643 (6.7) 152 (25.8) 452 (10.5) 29 (0.7) <0.001*
Discharge
medications
Aspirin, n (%) 8147
(85.2)
464 (79.2) 3626 (84.7) 3636 (87.9) <0.001*
ACE inhibitors, n (%) 7609
(79.5)
418 (71.3) 3389 (79.2) 3436 (83.1) <0.001*
Beta-blockers, n (%) 7592
(79.7)
430 (73.4) 3340 (78. 0) 3439 (83.1) <0.001*
Statin, n (%) 8140
(85.1)






502 (85.1) 3854 (90.3) 3877 (94.5) <0.001*
IMD Index of Multiple Deprivation, BMI body mass index, ACE angiotensin-converting enzyme, STEMI ST-elevation myocardial infarction, NSTEMI non-STEMI, CABG
coronary artery bypass grafting, PCI percutaneous coronary intervention, AMI acute myocardial infarction, COPD Chronic Obstructive Pulmonary Disease. †Obtained
from chi-squared or analysis of variance (ANOVA) as appropriate. *Significant after Hochberg correction using a false discovery rate of 0.05
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leaving an analytical cohort of 9566 patients (3908 STEMI,
5658 NSTEMI, Additional file 1: Figure S1 in the supple-
ment). The EQ-5D-3L questionnaire response rates were
97.5% (9332/9566), 74.7% (6679/8945), 63.9% (5572/
8719), and 62.7% (5047/8043) at hospitalisation, 1 month,
6 months, and 12 months, respectively. Reasons for non-
participation at each stage included death and withdrawals
from the study. Sixty-nine out of 9566 patients died in
hospital. There were significant differences in some base-
line characteristics between the patients who dropped out
and those who completed the study (Additional file 1:
Table S4).
Baseline demographic data were missing in less than
5% of cases, except for the Index of Multiple Deprivation
(IMD) (55.0%) and ethnicity (9.3%). Overall, 25.1%
(2,397) of the analytical cohort were women. The mean
age was 64.1 (standard deviation [SD] 11.9) years; mean
body mass index (BMI) 28.7 (6.04) kg/m2, median IMD
18.5 (interquartile range [IQR] 10.9 to 31.8), and 6248
(65.3%) were smokers or ex-smokers.
Long-term health conditions in MI patients
Frequently observed long-term health conditions in-
cluded hypertension 4078 (42.6%), angina 1792 (18.7%),
PVD 428 (4.5%), diabetes mellitus 1714 (17.9%), COPD
1166 (12.2%), CVSD 428 (4.5%), chronic renal failure
289 (3.0%), and heart failure 212 (2.2%). Overall, 53.5%
of participants (5119) had one or more long-term health
conditions; 3562 out of 9566 (37.2%) had none; 3157
(33.0%) had one, 1414 (14.8%) had two, 419 (4.4%) had
three, 110 (1.2%) had 4, and 19 (0.2%) had five or more
co-morbidities. Co-morbidity data were not recorded in
885 (9.3%) cases. Co-morbidities were more prevalent in
women (1442, 60.1%) than men (3674, 51.3%).
Multimorbidity clusters in MI patients
LCA identified three distinct multimorbidity classes and
were clinically labelled as class 1: severe multimorbidity,
591 (6.5%), class 2: moderate multimorbidity, 4301
(47.6%), and class 3: mild multimorbidity, 4147 (45.9%).
The majority of health conditions were more prevalent
in the severe class: diabetes (severe 64.7%; moderate
27.1%; and mild 2.6%), PVD (20.5%, 3.9% and 0.6%),
CVSD (20.6%, 6.9% and 0%), CRF (39.8%, 1.1% and
0.2%) and heart failure (34.4%, 0.0% and 0.1%), and
asthma or COPD (24.9%, 15.1% and 8.6%); however,
hypertension was more prevalent in the moderate class
(severe 69% moderate 76.6% and mild 8.1%) (Fig. 1).
Factors associated with multimorbidity class membership
Compared with the mild multimorbidity class, patients
in the severe and moderate multimorbidity classes were
older (mean age of 74.8, 68.8 vs 57.5 years), had a higher
proportion of women (30.0%, 29.7% vs 19.4%), more
commonly presented with NSTEMI (86.0%, 66.7% vs
49.3%) and more often had a history of angina (63.3%,
30.7% vs 1.9%), previous MI ( 65.0%, 23.4% vs 2.8%),
CABG (25.8%, 10.5% vs 0.7%), and previous PCI (28.7%,
14.4% vs 2.4%). Compared to the severe class, the mild
and moderate classes were more likely to have STEMI
(50.7% and 33.3% vs. 14.0%) (Table 1).
Fig. 1 Percent of patients with conditions in each multimorbidity class. Severe multimorbidity patients tended to have high levels of all co-
morbidities, moderate multimorbidity patients tended to have hypertension, and diabetes, and mild multimorbidity were patients with few co-
morbidities. Note COPD indicates chronic obstructive pulmonary disease; CVSD, cerebrovascular disease; PVD, peripheral vascular disease; CRF,
chronic renal failure
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Multimorbidity and perceptions of health state
Table 2 shows descriptive statistics for EQ-VAS scores
by multimorbidity clusters. Without adjustment for dif-
ferences in patient characteristics, perceptions of health
state measured by EQ-VAS scores were worse in the se-
vere multimorbidity class compared to the mild and
moderate classes suggesting better recovery of HRQoL
in the mild and moderate multimorbidity classes com-
pared to the severe class and these differences persisted
at 12 months (Fig. 2). Compared with the moderate and
mild classes, patients in the severe class had lower EQ-
VAS scores at hospitalisation (59.39 vs. 63.08, 64.57), at
30 days (58.95 vs 68.20, 71.73), 6 months (59.92 vs
71.38, 76.39), and 12 months (61.73 vs 72.05, 77.69).
Table 2 EQ-VAS and EQ-5D utility scores by follow-up time and multimorbidity class
Variable Multimorbidity class 1 (severe)
591 (6.5%)
Multimorbidity class 2 (moderate)
4301 (47.6%)




Baseline 0.62 (0.31) 0.71 (0.29) 0.75 (0.28) <0.001*
1 month 0.61 (0.30) 0.73 (0.26) 0.78 (0.24) <0.001*
6 months 0.60 (0.30) 0.75 (0.26) 0.82 (0.24) <0.001*
12 months 0.59 (0.30) 0.76 (0.27) 0.83 (0.24) <0.001*
Utilities: EQ-VAS,
mean (SD)
Baseline 59.39 (20.83) 63.08 (20.30) 64.57 (21.01) <0.001*
1 month 58.95 (19.36) 68.20 (18.27) 71.73 (17.73 <0.001*
6 months 59.92 (20.79) 71.38 (18.54) 76.39 (17.22) <0.001*
12 months 61.73 (19.43) 72.05 (18.60) 77.69 (17.31) 0.001*
EQ-5D dimensions
baseline
Mobility 398 (67.34) 1833 (42.62) 1048 (25.27) <0.001*
Self-care 163 (27.58) 690 (16.04) 399 (9.62) <0.001*
Activities 370 (62.61) 2115 (49.17) 1837 (44.30) <0.001*
Pain 288 (48.73) 1662 (38.64) 1178 (28.41) <0.001*
Anxiety and depression 221 (37.39) 1473 (34.25) 1381 (33.30) 0.081
EQ-5D 30 days
Mobility 264 (71.35) 1364 (43.86) 683 (24.03) <0.001*
Self-care 120 (32.61) 481 (15.49) 215 (7.58) <0.001*
Activities 275 (74.53) 1862 (60.06) 1498 (53.05) <0.001*
Pain 228 (61.79) 1484 (47.81) 1077 (38.08) <0.001*
Anxiety and depression 160 (43.72) 1152 (37.13) 1066 (37.54) 0.05
EQ-5D 6 months
Mobility 209 (70.13) 1149 (43.31) 538 (23.08) <0.001*
Self-care 97 (33.33) 387 (14.63) 173 (7.42) <0.001*
Activities 216 (71.76) 1220 (46.02) 766 (32.90) <0.001*
Pain 208 (69.57) 1280 (48.25) 808 (34.71) <0.001*
Anxiety and depression 129 (43.14) 821 (30.99) 730 (31.32) <0.001*
EQ-5D 12 months
Mobility 207 (76.10 1080 (44.68) 477 (22.60) <0.001*
Self-care 97 (35.27) 389 (16.11) 166 (7.88) <0.001*
Activities 203 (74.09) 1091 (45.19) 571 (27.05) <0.001*
Pain 195 (70.91) 1126 (46.94) 673 (32.08) <0.001*
Anxiety and depression 99 (36.00) 696 (28.88) 568 (26.92) 0.006*
Values are given as the mean (standard deviation) for EQ-VAS, EQ-5D utility scores. Values are given as frequencies (percentages) for EQ-5D dimensions.
*Significant after Hochberg correction using a false discovery rate of 0.05
Munyombwe et al. BMC Medicine          (2021) 19:227 Page 7 of 14
Multimorbidity and HRQoL measured by EQ-5D
Responses from the EQ-5D dimensions showed that
during hospitalisation, 69.1% (6607/9566) of partici-
pants reported ≥ one problem across the EQ-5D di-
mensions, which increased to 73.9% (4935/6679) at 1
month, decreased to 62.6% (3491/5572) at 6 months,
and 59.7% (3011/5047) at 12 months. Overall, the most
frequently reported problems at baseline were for activ-
ities (50.1%), followed by mobility (37.6%), pain (35.5%),
anxiety and depression (35.4%), and self-care (14.4%).
At 12 months, they were pain (41.8%), followed by
activities (38.8%), mobility (36.7%), anxiety and de-
pression (28.6%), and self-care (13.6%). Table 2 shows
descriptive statistics for EQ-5D scores by multimor-
bidity clusters.
Compared with the mild class, the percentage report-
ing ≥ 1 problem on the EQ-5D dimension at hospitalisa-
tion was higher in the severe and moderate classes
(severe 85.3%; moderate 72.8% vs mild 65.5%), at 1
month (89.2%, 76.1% vs 69.0%), 6 months (85.9%, 67.5%
vs 53.9%), and 12 months (88.6%, 65.3% vs 49.2%). At
hospitalisation, individuals in the severe class were more
likely to report having problems in all EQ-5D
dimensions compared to the moderate and mild classes:
mobility (severe 67.3% vs. mild 42.6%, mild 25.3%, re-
spectively), self-care (27.6% vs 16.0%, 9.6%), activities
(62.6% vs 49.2%, 44.3%), pain (48.7%% vs. 38.6%, 28.4%),
anxiety and depression (37.4% vs 34.3%, 33.3%), and the
prevalence of problems continued to be higher in the se-
vere class at 1, 6, and 12 months. Individuals in the se-
vere class were also likely to report problems with
mobility, self-care, activities, pain, anxiety, and depres-
sion at 1, 6, and 12 months (Table 2). Compared with
the moderate and mild classes, patients in the severe
class had lower EQ-5D scores at hospitalisation (0.62 vs.
0.71, 0.75), at 30 days (0.61 vs 0.73, 0.78), 6 months
(0.60 vs 0.75, 0.82), and 12 months (0.59 vs 0.76, 0.83).
Adjusted results from multilevel modelling of longitudinal
EQ-VAS, EQ-5D scores, and multimorbidity classes
Compared with the baseline, the adjusted average health
state scores improved at 1 month (difference 4.62, 95%
CI 4.04 to 5.19) and 6 months (3.43, 2.11 to 4.75), but
declined at 12 months (−1.10, −3.55 to 1.35) suggesting
a poorer health state at 12 months and greatest improve-
ment at one month (Table 3). After adjusting for covari-
ates, compared to the mild multimorbidity class,
increased multimorbidity was associated with a signifi-
cant decline in EQ-VAS scores (adjusted coefficient:
−5.12 [95% CI −7.04 to −3.19] and −0.98 [−1.93 to
−0.04] for severe and moderate multimorbidity, respect-
ively. Similarly, increased multimorbidity was associated
with a decline in EQ-5D scores (adjusted coefficient:
−0.16 [95% CI −0.18 to −0.13] and −0.05 [−0.06 to
Fig. 2 Temporal changes of HRQoL by multimorbidity class. The EQ-VAS scores range from 0 (worst) to 100 (best) health status with a difference
of 7 points considered clinically meaningful. Patients with severe multimorbidity have worse health-related quality of life, shown by EQ-VAS
scores, at baseline and through 12 months of follow-up
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−0.04] for severe and moderate multimorbidity classes,
respectively (Additional file 1: Table S5).
Adjusted results from multilevel modelling of longitudinal
EQ-5D dimensions and multimorbidity classes
The multilevel logistic regression analysis results for the
association of multimorbidity classes with five EQ-5D di-
mensions are shown in Fig. 3. After adjustment, individ-
uals in the severe class were more likely than those in
the mild class to report problems in mobility, OR 9.62
(95% confidence interval: 6.44 to 14.36), self-care 7.87
(4.78 to 12.97), activities 2.41 (1.79 to 3.26), pain 2.04
(1.50 to 2.77), and anxiety/depression 1.97 (1.42 to 2.74).
Similarly, individuals in the moderate class were more
likely than those in the mild class to report problems
with their mobility: 2.21 (1.82 to 2.69), self-care 2.05
(1.56 to 2.69), activities 1.10 (0.95 to 1.27), pain 1.33
(1.14 to 1.55), and anxiety/depression 1.26 (1.07 to 1.48).
Discussion
In this nationwide study of 9566 patients with MI who
were followed for 1 year, multimorbidity was common
and associated with low HRQoL. Uniquely, our study
identifies three distinct clusters of multimorbidity: severe
(older/multiple chronic conditions), moderate (older/
hypertension/diabetes), and mild (younger/low rates of
chronic conditions). Different patterns of multimorbidity
were associated with different HRQoL trajectories. We
found an inverse relationship between extent of multi-
morbidity and improvement in HRQoL over time. Those
with a high burden of multimorbidity at baseline had
poor HRQoL, which failed to recover following MI. Not-
ably, the EQ-VAS scores reported in patients with MI
across all three multimorbidity classes were lower than
those which have been reported in other common
chronic conditions such as COPD [43] and heart failure
[44], and UK general population [45]. Severe baseline
multimorbidity was adversely associated with the EQ-5D
dimensions mobility, self-care, activities, pain, anxiety,
and depression. Indeed, severe multimorbidity was asso-
ciated with an average decrease of 5 points in EQ-VAS
scores compared to the mild multimorbidity cluster.
Older MI survivors with high rates of multimorbidity,
and patients with hypertension and diabetes are more
likely to be associated with poor HRQoL.
Several previous studies have looked at the associa-
tions of individual chronic health conditions and health-
related quality of life but a few focussed on combina-
tions of disease clusters and their impact on health-
related quality of life in MI survivors. Our study made a
contribution to existing research by investigating the im-
pact of different multimorbidity clusters on changes in
HRQoL in MI survivors. Understanding disease clusters
and their impact on HRQoL provides more insight for
designing patient-centred care interventions. Our
findings are consistent with previous studies that have
found a decline in health-related quality of life in pa-
tients with hypertension, diabetes [46–48], and lung dis-
eases [14, 19]. Such chronic conditions are related with
stress, and their co-existence may accentuate the impact
on psychological wellbeing owing to care demands [23].
Similar to other previous studies, we found a significant
association between increased multimorbidity and anx-
iety and depression. This finding is consistent with pre-
vious research that reported an association between
depression and cardiovascular diseases [49, 50]. Whilst it
is known that a greater burden of comorbidities is asso-
ciated with increased depression and other mental health
conditions [1], the complex interplay between these re-
mains unclear [50].
Our findings have similarities and differences from an-
other study [51] that found five distinct multimorbidity
patterns in Asian patients with heart failure.
Table 3 Adjusted parameter estimates from multilevel
modelling of EQ-VAS scores and multi-morbidity classes,




Intercept 48.39 (40.06 to 56.72)
Month, baseline (ref)
1 month 4.62 (4.04 to 5.19) <0.001*
6 months 3.43 (2.11 to 4.75) <0.001*
12 months −1.10 (−3.55 to 1.35) 0.38
Multimorbidity classes
Mild (ref)
Moderate −0.98 (−1.93 to −0.04) 0.04
Severe −5.12 (−7.04 to −3.19) <0.001*
Diagnosis(STEMI) ref
Diagnosis (NSTEMI) −0.26 (−1.19 to 0.65) 0.57
Age 0.12 (0.08 to 0.15) <0.001*
Women −4.17 (−5.02 to −3.32) <0.001*
Ethnicity White 0.81 (−1.61 to 3.24 0.51
Ex/current smoking status −1.07 (−1.84 to -0.30) 0.01
Previous MI −1.37 (−2.64 to −0.10) 0.03
Previous Angina −2.15 (−3.27 to −1.04) <0.001*
Treatments
Previous PCI −1.53 (−2.96 to 0.11) 0.035
Previous CABG surgery −3.03 (−4.64 to −1.42) <0.001*
Adjusting for age, sex, ethnicity (white versus other) smoking status (never vs
ex or current), past medical history of MI, angina, diagnosis (STEMI or NSTEMI),
revascularisation (percutaneous coronary intervention [PCI] vs. no PCI;
coronary artery bypass graft [CABG] surgery vs no CABG surgery), medications
(B-blockers, statins, ACE, aspirin), cardiac rehabilitation (yes/no), and
interactions of time and multimorbidity. Note: CABG coronary artery bypass
grafting, PCI percutaneous coronary intervention, MI myocardial infarction,
STEMI ST-elevation myocardial infarction, NSTEMI non-ST-elevation myocardial
infarction, *Significant after Hochberg correction using a false discovery rate
of 0.05
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Fig. 3 (See legend on next page.)
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Discrepancies in number of classes between our study
and that by Tromp et al. could be due to differences in
the cohort health conditions. The study by Tromp et al.
used a cohort of patients with heart failure, whilst our
cohort were patients with myocardial infarction. Fur-
thermore, we classified patients using 7 health condi-
tions whilst the study by Tromp et al. used more than 7
health conditions including those that were not available
in our study such as coronary artery disease, previous
stroke, chronic kidney disease, peptic ulcer, cancer, liver
disease, and dementia. Similar to our study, Tromp et al.
identified a class with a high probability of having hyper-
tension and diabetes and a class with low comorbidity
rates.
Similar to our findings a UK study [4] using the same 7
health conditions that we used in our study found three
distinct multimorbidity patterns in patients with myocar-
dial infarction. There are similarities and differences in co-
morbidities combinations between our clusters and those
found by Hall et al. The three multimorbidity patterns re-
ported by Hall et al. were elderly with high multimorbidity
(tended to have heart failure, PVD, and hypertension),
medium multimorbidity patterns (tended to have PVD
and hypertension), and younger with low multimorbidity
(patients with few comorbidities). We also found an eld-
erly high multimorbidity cluster with high comorbidities
and a younger, low multimorbidity cluster with few co-
morbidities. However, the multimorbidity patterns were
different between our medium multimorbidity cluster and
that reported by Hall et al. The medium multimorbidity
cluster reported in our study tended to have diabetes and
hypertension whilst that reported by Hall et al. tended to
have PVD and hypertension. These discrepancies could be
due to different cohorts used by the two studies. Hall’s
study used the MINAP registry which is much bigger (n=
693,388) and more representative of the target population
than the EMMACE cohort (n=9566) which comprises of a
select cohort of patients who volunteered to participate in
the study hence may exhibit selection bias. Furthermore,
the EMMACE study excluded patients at a terminal stage
of any illness, and those for whom follow-up was inappro-
priate or impractical. The study by Hall et al. had older
patients with mean age 70.7 years compared to 64 years
for the EMMACE study. Latent class analysis applied to a
larger cohort may yield a different number of classes with
different patterns [52]; therefore, there is need for more
research to externally validate our study findings.
Strengths and limitations
To our knowledge, this is the first study to map the dis-
tribution of different co-morbidity patterns among pa-
tients with MI and determine their impact on temporal
changes in HRQoL using a large nationwide longitudinal
cohort study. The breadth of the data increases general-
isability, but with sufficient depth to allow multi-level
modelling, and latent class analysis. We have extended
previous knowledge by identifying distinct multimorbid-
ity clusters and their impact on HRQoL in MI survivors.
The EQ-5D captures important aspects of health status
that may be affected by an MI, including mobility, activ-
ities, self-care, depression or anxiety, and pain. Whilst
we recognise that using a disease-specific metric may
have added additional insights, use of a generic tool
allowed us to interpret the findings in the context of a
range of other clinical conditions. Limitations of this
work include the potential for participation bias and sur-
vivorship bias, in common with all such studies. In this
study, multimorbidity classes were determined using
seven health conditions that were recorded in the
MINAP registry, more research using more health con-
ditions is needed and to investigate whether the multi-
morbidity clusters change over time using latent
transition models.
Clinical implications
The identification of multimorbidity patterns and their
impact on changes in HRQoL, and EQ-5D domains
(mobility, activities, pain, anxiety, and depression) may
help inform the design of targeted interventions [23],
whereby therapies that better control co-morbidities in
MI survivors may translate into meaningful improve-
ment in HRQoL. Furthermore, patients with very high
levels of multimorbidity might benefit from an early
multidisciplinary team involvement to directly improve
specific domains of their HRQoL. Multidisciplinary ef-
forts to effectively manage cardiovascular risk factors
(particularly diabetes and hypertension) may have an
additional secondary preventive role.
Conclusion
This multi-centre longitudinal study of over 9500 survi-
vors of hospitalised MI found that multimorbidity was
adversely associated with dimensions of HRQoL includ-
ing mobility, self-care, and activities of daily living, pain,
anxiety, and depression. Moreover, a data-driven
(See figure on previous page.)
Fig. 3 Association of multimorbidity classes and EQ-5D dimensions, (Mobility, Self-care, Activities, Pain and Anxiety/depression), odds ratios and
95% confidence intervals (reference group, mild multimorbidity). Adjusting for age, sex, ethnicity (white versus other) smoking status (never vs ex
or current), past medical history of MI, angina, diagnosis (STEMI or NSTEMI), revascularisation (percutaneous coronary intervention [PCI] vs. no PCI;
coronary artery bypass graft [CABG] surgery vs no CABG surgery), cardiac rehabilitation (yes/no) and interactions of time and multimorbidity,
and medications
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approach has enabled the identification of three clinic-
ally distinct multimorbidity clusters with significant
differences in HRQoL and who may be suitable for tai-
lored interventions to improve and maintain their
HRQoL following MI. Older survivors of MI with high
rates of multimorbidity, and patients with hypertension
and diabetes are more likely to be associated with poor
HRQoL. As such, we recommend specific interventions
to target these subgroups to improve their HRQoL.
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